A recent study published in the New England Journal of Medicine examined the effectiveness and safety of obicetrapib for patients at high risk of cardiovascular events.
LDL-Lowering Drugs and CETP Inhibition
Numerous clinical trials have demonstrated that lowering LDL cholesterol can reduce the risk of heart-related events.
Obicetrapib belongs to a class of drugs known as cholesteryl ester transfer protein (CETP) inhibitors, which have been studied for their potential to modify cholesterol levels. However, the development of CETP inhibitors has faced challenges.
For example, torcetrapib was linked to higher rates of cardiovascular problems and death, while other drugs like dalcetrapib and evacetrapib were discontinued due to their failure to improve cardiovascular outcomes.
These challenges have influenced the development of newer drugs like obicetrapib. Designed with a hydrophilic structure to minimize side effects, obicetrapib effectively lowers LDL cholesterol levels while also increasing HDL cholesterol.
Combination Therapy for High-Risk Patients
For patients at very high risk of cardiovascular events, combination therapy is often necessary to lower LDL cholesterol.
Despite its potential, combination lipid-lowering therapy is underused, as shown by observational studies, leading to many high-risk patients not receiving adequate treatment and facing greater risks of cardiovascular problems.
Early trials of obicetrapib have shown it successfully lowers LDL cholesterol and increases HDL cholesterol levels. When added to the maximum tolerated dose of existing lipid-lowering therapy, obicetrapib helps high-risk patients reach their LDL cholesterol targets. Alongside its impact on lipid levels, ongoing studies are closely examining the safety and side effects of obicetrapib in this patient group
Related topics: